MICROCATCH: EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL PATHOLOGIES FROM LIQUID BIOPSIES (Q4192986): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
MICROCATCH: EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL PATHOLOGIES FROM LIQUID BIOPSIES | |||||||||||||||
| Property / summary | |||||||||||||||
BRAINDTECH HAS DEVELOPED A SYSTEM OF EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL DISEASES BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. MICROVESICLES ARE PRODUCED ABOUT 10 YEARS BEFORE CLINICAL SYMPTOMS OF PATHOLOGY. BRAINDTECH IDENTIFIES PATHOLOGICAL-SPECIFIC PATTERNS OF MICRORNA CONTAINED IN MICROVESICLES, ISOLATED FROM LIQUID BIOPSIES. MICROVESICLES ARE CAPTURED USING A MICROFLUIDIC CHIP DEVELOPED BY IBM. BRAINDTECH HAS COVERED ITS INVENTIONS WITH TWO PATENTS, ONE RELATING TO THE METHOD FOR THE DIAGNOSIS, PROGNOSIS AND THERAPEUTIC MONITORING OF NEUROLOGICAL, NEURODEGENERATIVE AND INFLAMMATORY PATHOLOGIES, BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. THE SECOND RELATED TO THE IDENTIFICATION IN THE BLOOD OF SPECIFIC MICROGLIA MARKERS, AIMED AT ASSESSING DAMAGE TO BLOOD-BRAIN BARRIER FOR DIAGNOSTIC PURPOSES RELATED TO CRANIAL TRAUMA AND NEURODEGENERATIVE AND/OR NEUROIN PATHOLOGIES (English) | |||||||||||||||
| Property / summary: BRAINDTECH HAS DEVELOPED A SYSTEM OF EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL DISEASES BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. MICROVESICLES ARE PRODUCED ABOUT 10 YEARS BEFORE CLINICAL SYMPTOMS OF PATHOLOGY. BRAINDTECH IDENTIFIES PATHOLOGICAL-SPECIFIC PATTERNS OF MICRORNA CONTAINED IN MICROVESICLES, ISOLATED FROM LIQUID BIOPSIES. MICROVESICLES ARE CAPTURED USING A MICROFLUIDIC CHIP DEVELOPED BY IBM. BRAINDTECH HAS COVERED ITS INVENTIONS WITH TWO PATENTS, ONE RELATING TO THE METHOD FOR THE DIAGNOSIS, PROGNOSIS AND THERAPEUTIC MONITORING OF NEUROLOGICAL, NEURODEGENERATIVE AND INFLAMMATORY PATHOLOGIES, BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. THE SECOND RELATED TO THE IDENTIFICATION IN THE BLOOD OF SPECIFIC MICROGLIA MARKERS, AIMED AT ASSESSING DAMAGE TO BLOOD-BRAIN BARRIER FOR DIAGNOSTIC PURPOSES RELATED TO CRANIAL TRAUMA AND NEURODEGENERATIVE AND/OR NEUROIN PATHOLOGIES (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: BRAINDTECH HAS DEVELOPED A SYSTEM OF EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL DISEASES BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. MICROVESICLES ARE PRODUCED ABOUT 10 YEARS BEFORE CLINICAL SYMPTOMS OF PATHOLOGY. BRAINDTECH IDENTIFIES PATHOLOGICAL-SPECIFIC PATTERNS OF MICRORNA CONTAINED IN MICROVESICLES, ISOLATED FROM LIQUID BIOPSIES. MICROVESICLES ARE CAPTURED USING A MICROFLUIDIC CHIP DEVELOPED BY IBM. BRAINDTECH HAS COVERED ITS INVENTIONS WITH TWO PATENTS, ONE RELATING TO THE METHOD FOR THE DIAGNOSIS, PROGNOSIS AND THERAPEUTIC MONITORING OF NEUROLOGICAL, NEURODEGENERATIVE AND INFLAMMATORY PATHOLOGIES, BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. THE SECOND RELATED TO THE IDENTIFICATION IN THE BLOOD OF SPECIFIC MICROGLIA MARKERS, AIMED AT ASSESSING DAMAGE TO BLOOD-BRAIN BARRIER FOR DIAGNOSTIC PURPOSES RELATED TO CRANIAL TRAUMA AND NEURODEGENERATIVE AND/OR NEUROIN PATHOLOGIES (English) / qualifier | |||||||||||||||
point in time: 31 January 2022
| |||||||||||||||
Revision as of 18:47, 31 January 2022
Project Q4192986 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MICROCATCH: EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL PATHOLOGIES FROM LIQUID BIOPSIES |
Project Q4192986 in Italy |
Statements
37,107.74 Euro
0 references
74,215.47 Euro
0 references
50.0 percent
0 references
BRAINDTECH S.R.L.
0 references
BRAINDTECH HA SVILUPPATO UN SISTEMA DI DIAGNOSI PRECOCE, PROGNOSI E MONITORAGGIO DI MALATTIE NEUROLOGICHE BASATO SULLÂ ANALISI DEI MICRORNA CONTENUTI NELLE MICROVESCICOLE MICROGLIALI. LE MICROVESCICOLE SONO PRODOTTE CIRCA 10 ANNI PRIMA DEI SINTOMI CLINICI DI PATOLOGIA. BRAINDTECH IDENTIFICA PATTERN PATOLOGIA-SPECIFICI DI MICRORNA CONTENUTI IN MICROVESCICOLE MICROGLIALI, ISOLATE DA BIOPSIE LIQUIDE. LE MICROVESCICOLE VENGONO CATTURATE UTILIZZANDO UN CHIP MICROFLUIDICO SVILUPPATO DA IBM. BRAINDTECH HA COPERTO LE SUE INVENZIONI CON DUE BREVETTI, UNO RELATIVO AL METODO PER LA DIAGNOSI, LA PROGNOSI ED IL MONITORAGGIO TERAPEUTICO DI PATOLOGIE NEUROLOGICHE, NEURODEGENERATIVE E INFIAMMATORIE, BASATO SULL'ANALISI DEI MICRORNA CONTENUTI NELLE MICROVESCICOLE MICROGLIALI. IL SECONDO RELATIVO ALLÂ IDENTIFICAZIONE NEL SANGUE DI MARCATORI MICROGLIA SPECIFICI, FINALIZZATI A VALUTARE DANNI DI BARRIERA EMATOENCEFALICA PER SCOPI DIAGNOSTICI LEGATI A TRAUMI CRANICI E PATOLOGIE NEURODEGENERATIVE E/O NEUROIN (Italian)
0 references
BRAINDTECH HAS DEVELOPED A SYSTEM OF EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL DISEASES BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. MICROVESICLES ARE PRODUCED ABOUT 10 YEARS BEFORE CLINICAL SYMPTOMS OF PATHOLOGY. BRAINDTECH IDENTIFIES PATHOLOGICAL-SPECIFIC PATTERNS OF MICRORNA CONTAINED IN MICROVESICLES, ISOLATED FROM LIQUID BIOPSIES. MICROVESICLES ARE CAPTURED USING A MICROFLUIDIC CHIP DEVELOPED BY IBM. BRAINDTECH HAS COVERED ITS INVENTIONS WITH TWO PATENTS, ONE RELATING TO THE METHOD FOR THE DIAGNOSIS, PROGNOSIS AND THERAPEUTIC MONITORING OF NEUROLOGICAL, NEURODEGENERATIVE AND INFLAMMATORY PATHOLOGIES, BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. THE SECOND RELATED TO THE IDENTIFICATION IN THE BLOOD OF SPECIFIC MICROGLIA MARKERS, AIMED AT ASSESSING DAMAGE TO BLOOD-BRAIN BARRIER FOR DIAGNOSTIC PURPOSES RELATED TO CRANIAL TRAUMA AND NEURODEGENERATIVE AND/OR NEUROIN PATHOLOGIES (English)
31 January 2022
0 references
BRESSO
0 references